Sevelamer Carbonate Patent Expiration
Sevelamer Carbonate is Used for managing high levels of phosphate in the blood, often in patients with chronic kidney disease. It was first introduced by Sanofi Genzyme
Sevelamer Carbonate Patents
Given below is the list of patents protecting Sevelamer Carbonate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Renvela | US9095509 | Sachet formulation for amine polymers | Dec 06, 2030 | Genzyme |
| Renvela | US7985418 | Aliphatic amine polymer salts for tableting | Oct 27, 2025 | Sanofi |
| Renvela | US5667775 | Phosphate-binding polymers for oral administration |
Sep 16, 2014
(Expired) | Genzyme |
| Renvela | US5667775 | Phosphate-binding polymers for oral administration |
Sep 16, 2014
(Expired) | Sanofi |
| Renvela | US5496545 | Phosphate-binding polymers for oral administration |
Aug 11, 2013
(Expired) | Genzyme |
| Renvela | US5496545 | Phosphate-binding polymers for oral administration |
Aug 11, 2013
(Expired) | Sanofi |
| Renvela | US6509013 | Method of making phosphate-binding polymers for oral administration |
Aug 11, 2013
(Expired) | Genzyme |
| Renvela | US6509013 | Method of making phosphate-binding polymers for oral administration |
Aug 11, 2013
(Expired) | Sanofi |
| Renvela | US6858203 | Method of making phosphate-binding polymers for oral administration |
Aug 11, 2013
(Expired) | Genzyme |
| Renvela | US6858203 | Method of making phosphate-binding polymers for oral administration |
Aug 11, 2013
(Expired) | Sanofi |
| Renvela | US7014846 | Phosphate-binding polymers for oral administration |
Aug 11, 2013
(Expired) | Genzyme |
| Renvela | US7014846 | Phosphate-binding polymers for oral administration |
Aug 11, 2013
(Expired) | Sanofi |
| Renvela | US7459151 | Phosphate-binding polymers for oral administration |
Aug 11, 2013
(Expired) | Genzyme |
| Renvela | US7459151 | Phosphate-binding polymers for oral administration |
Aug 11, 2013
(Expired) | Sanofi |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Sevelamer Carbonate's patents.
Latest Legal Activities on Sevelamer Carbonate's Patents
Given below is the list recent legal activities going on the following patents of Sevelamer Carbonate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 18 Jan, 2023 | US9095509 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 Jan, 2023 | US7985418 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 May, 2020 | US7459151 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 24 Jan, 2019 | US9095509 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Jan, 2019 | US7985418 |
| Patent Issue Date Used in PTA Calculation Critical
| 04 Aug, 2015 | US9095509 |
| Recordation of Patent Grant Mailed Critical
| 04 Aug, 2015 | US9095509 |
| Issue Notification Mailed Critical
| 15 Jul, 2015 | US9095509 |
| Application Is Considered Ready for Issue Critical
| 07 Jul, 2015 | US9095509 |
| Dispatch to FDC | 07 Jul, 2015 | US9095509 |
Sevelamer Carbonate's Family Patents
